Turgeon V L, Houenou L J
Department of Neurobiology and Anatomy, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA.
Brain Res Brain Res Rev. 1997 Sep 30;25(1):85-95. doi: 10.1016/s0165-0173(97)00015-5.
There is increasing evidence suggesting that members of the serine protease family, including thrombin, chymotrypsin, urokinase plasminogen activator, and kallikrein, may play a role in normal development and/or pathology of the nervous system. Serine proteases and their cognate inhibitors have been shown to be increased in the neural parenchyma and cerebrospinal fluid following injury to the blood brain barrier. Zymogen precursors of thrombin and thrombin-like proteases as well as their receptors have also been localized in several distinct regions of the developing or adult brain. Thrombin-like proteases have been shown to exert deleterious effects, including neurite retraction and death, on different neuronal and non-neuronal cell populations in vitro. These effects appear to be mediated through cell surface receptors and can be prevented or reversed with specific serine protease inhibitors (serpins). Furthermore, we have recently shown that treatment with protease nexin-1 (a serpin that inhibits thrombin-like proteases) promotes the survival and growth of spinal motoneurons during the period of programmed cell death and following injury. Taken together, these observations suggest that thrombin-like proteases play a deleterious role, whereas serpins promote the development and maintenance of neuronal cells. Thus, changes in the balance between serine proteases and their cognate inhibitors may lead to pathological states similar to those associated with some neurodegenerative diseases such as Alzheimer's disease. The present review summarizes the current state of research involving such serine proteases and speculates on the possible role of these thrombin-like proteases in the development, plasticity and pathology of the nervous system.
越来越多的证据表明,丝氨酸蛋白酶家族成员,包括凝血酶、胰凝乳蛋白酶、尿激酶型纤溶酶原激活剂和激肽释放酶,可能在神经系统的正常发育和/或病理过程中发挥作用。血脑屏障受损后,神经实质和脑脊液中的丝氨酸蛋白酶及其同源抑制剂已被证明会增加。凝血酶和凝血酶样蛋白酶的酶原前体及其受体也已定位在发育中的或成体大脑的几个不同区域。凝血酶样蛋白酶已被证明在体外对不同的神经元和非神经元细胞群体产生有害影响,包括神经突回缩和死亡。这些影响似乎是通过细胞表面受体介导的,并且可以用特异性丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂)预防或逆转。此外,我们最近表明,在程序性细胞死亡期间和损伤后,用蛋白酶nexin-1(一种抑制凝血酶样蛋白酶的丝氨酸蛋白酶抑制剂)治疗可促进脊髓运动神经元的存活和生长。综上所述,这些观察结果表明,凝血酶样蛋白酶起有害作用,而丝氨酸蛋白酶抑制剂促进神经元细胞的发育和维持。因此,丝氨酸蛋白酶与其同源抑制剂之间平衡的变化可能导致与某些神经退行性疾病(如阿尔茨海默病)相关的病理状态。本综述总结了涉及此类丝氨酸蛋白酶的研究现状,并推测了这些凝血酶样蛋白酶在神经系统发育、可塑性和病理过程中的可能作用。